Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 4/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550041 | 0.84 | RAPGEF4 (0.37) | RAPGEF4CES2CES1ACHEPTGS1 | |
| SCHEMBL531337 | 0.77 | CES2 (0.52) | RAPGEF4CES2CES1RIPK1ALDH1A1 | |
| SCHEMBL8446400 | 0.77 | RAPGEF4 (0.43) | RAPGEF4CES2CES1ACHEPTGS1 | |
| SCHEMBL30867014 | 0.77 | RAPGEF4 (0.43) | RAPGEF4CES2CES1ACHEPTGS1 | |
| SCHEMBL8268053 | 0.77 | RAPGEF4 (0.52) | RAPGEF4ACHEALDH1A1CA1 | |
| Chloromethane SCHEMBL27844640 | 0.75 | CES2 (0.46) | RAPGEF4CES2CES1RIPK1ALDH1A1 | |
| SCHEMBL30567470 | 0.73 | RAPGEF4 (0.38) | RAPGEF4CES2CES1ACHE | |
| SCHEMBL823681 | 0.73 | RAPGEF4 (0.38) | RAPGEF4CES2CES1ACHE | |
| SCHEMBL24369309 | 0.72 | RAPGEF4 (0.31) | RAPGEF4PTGS1PTGS2 | |
| SCHEMBL11992628 | 0.72 | RAPGEF4 (0.34) | RAPGEF4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1696 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260058204-A1 | ELECTROLYTE COMPOSITION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY CONTAINING THE SAME | HYUNDAI MOTOR CO LTD (KR) | 2026-02-26 | — | — | US | claimed |
| EP-1267906-A1 | LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | claimed |
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | claimed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001072324-A1 | LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| EP-4283734-B1 | ELECTROLYTE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING SAME | SAMSUNG SDI CO LTD (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-12633526-B2 | Electrode for rechargeable lithium battery and rechargeable lithium battery including same | SAMSUNG SDI CO., LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| CN-115911298-B | Positive electrode active material, method of preparing the same, and rechargeable lithium battery including the same | 三星SDI株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-12626902-B2 | Electrode for rechargeable lithium battery, electrode assembly and rechargeable lithium battery including the same | SAMSUNG SDI CO., LTD. (KR) | 2026-05-12 | — | — | US | disclosed |
| EP-4080610-B1 | A MANUFACTURING METHOD OF A NEGATIVE ACTIVE MATERIAL FOR A LITHIUM SECONDARY BATTERY, A NEGATIVE ACTIVE MATERIAL FOR A LITHIUM SECONDARY BATTERY, AND A LITHIUM SECONDARY BATTERY CONTAINING THIS NEGATIVE ACTIVE MATERIAL | POSCO (KR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4228025-B1 | NEGATIVE ELECTRODE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING SAME | SAMSUNG SDI CO LTD (KR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4163994-B1 | NEGATIVE ELECTRODE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING SAME | SAMSUNG SDI CO LTD (KR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2001072324-A1 | LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. | 2001-09-06 | — | — | US | disclosed |
| US-6235764-B1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| WO-2000039088-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| US-6057480-A | Process for preparing fluoroaryl magnesium derivative and process for preparing (fluoroaryl) borane compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0838466-A2 | Producing process of (fluoroaryl) borane compound and producing process of tetrakis (fluoroaryl) borate derivative | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0825195-A1 | PROCESS FOR THE PREPARATION OF FLUORINATED ARYLMAGNESIUM DERIVATIVES AND PROCESS FOR THE PREPARATION OF (FLUORINATED ARYL)BORON COMPOUNDS | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
| EP-0394644-A2 | Halobenzene derivatives | BAYER AG (DE) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12633526-B2 | Electrode for rechargeable lithium battery and rechargeable lithium battery including same | CACNA2D2, CACNA2D4, CACNA2D1 | RAPGEF4 2209/4885CES2 2077/4885CES1 3917/4885 |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | RAPGEF4 3832/4885CES2 2476/4885CES1 283/4885 |
| US-20260058204-A1 | ELECTROLYTE COMPOSITION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY CONTAINING THE SAME | KCNN2, DYRK1B, SETDB1 | RAPGEF4 3674/4885CES2 2767/4885CES1 4595/4885 |
| US-12626902-B2 | Electrode for rechargeable lithium battery, electrode assembly and rechargeable lithium battery including the same | SLC9A2, SLC9A1, SLC9B2 | RAPGEF4 1828/4885CES2 624/4885CES1 2408/4885 |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BACE1, APP, APH1A | RAPGEF4 2254/4885CES2 1767/4885CES1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.